Pakistan has a growing pharmaceutical market valued at $2.6 billion in 2015. Systemic anti-infectives and alimentary tract and metabolism drugs make up nearly half of total market share. The top 20 pharmaceutical companies, including GlaxoSmithKline and Abbott Laboratories, account for over 50% of total market value. Major trading partners for pharmaceutical imports and exports include Afghanistan, Denmark, Switzerland, and Germany.

1. PAKISTAN PHARMACEUTICAL MARKET
OVERVIEW
Muhammad Ali
email: phr_ali91@hotmail.com

2. Phr_ali91@hotmail.com
Pakistan
Muhammad Ali 2
o Officially Name Islamic Republic of Pakistan
o Capital Islamabad
o National languages Urdu
o Currency Pakistani rupee (₨) (PKR)
o Provinces : 4
Area: 796,095 sq km
Location:
Southern Asia, bordering the Arabian Sea, between
India on the east and Iran and Afghanistan on the
west and China in the north
Time difference: UTC+5

3. Phr_ali91@hotmail.com
Pakistan
• Population:
199,085,847 (July 2015 est.)
• Age structure:
0-14 years: 32.65% (male 33,396,847/female 31,611,641)
15-24 years: 21.44% (male 22,016,207/female 20,673,562)
25-54 years: 36.28% (male 37,526,930/female 34,701,271)
55-64 years: 5.28% (male 5,254,347/female 5,253,526)
65 years and over: 4.35% (male 4,036,727/female 4,614,789) (2015 est.)
• Population growth rate:
1.46% (2015 est.)
• Death rate:
6.49 deaths /1,000 population (2015 est.)
• Life expectancy at birth:
total population: 67.39 years
male: 65.47 years
female: 69.4 years (2015 est.)
Muhammad Ali 3

4. Phr_ali91@hotmail.com
Pakistan
Economy
• GDP (official exchange rate): $247.8 billion (2015 est.)
• GDP - real growth rate: 4% (2014 est.)
• GDP - per capita (PPP): $4,700 (2014 est.)
• Industrial production growth rate: 4.5% (2014 est.)
• Inflation rate (consumer prices): 8.6% (2014 est.)
• Exports: $24.8 billion (2014 est.)
• Budget:
revenues: $38.75 billion
expenditures: $53.11 billion (2015 est.)
• Exchange rates: Pakistani rupees (PKR) per US dollar -105 (FY2015
est.)
Muhammad Ali 4

5. Phr_ali91@hotmail.com
Pakistan
Healthcare
• Health expenditures:
2.8% of GDP (2013)
• Physicians density:
0.83 physicians/1,000 population (2010)
• Hospital bed density:
0.6 beds/1,000 population (2012)
• Major infectious diseases:
• degree of risk: high
• food or waterborne diseases: bacterial diarrhea, hepatitis A and E, and
typhoid fever
• vector borne diseases: dengue fever and malaria
• animal contact disease: rabies
• note: highly pathogenic H5N1 avian influenza has been identified in this
country; it poses a negligible risk with extremely rare cases possible
among US citizens who have close contact with birds (2013)
Muhammad Ali 5

6. Phr_ali91@hotmail.com
Healthcare System Structure
Muhammad Ali 6
ENTIRE COUNTRY
Total Hospitals 1217
Dispensaries 5377
Maternity & Child Welfare Centers 697
Beds in hospitals & dispensaries etc. 1,01,960
Total Doctors 151248
Total Dentist 15514
Total Surgeons 34187
Total Nurses 69,313
Retail Pharmacy Market 65,000

7. Phr_ali91@hotmail.com
Pakistan Pharmaceutical Overview
• Total Registered Pharmaceutical in Pakistan approximately 660
• Multinational Pharmaceutical Company 18
• National Pharmaceutical Company 641
• Estimated size of the Pharmaceutical market is US$ 2.6 Billion (IMS Q4,
2015)
• Projected Growth of Market is 13.06% in 2016
• 1% of profit of All Registered Pharmaceutical to MOH for R&D Expenditure
• This again makes the country the region's 7th most attractive market in
Asia.
Muhammad Ali 7

8. Phr_ali91@hotmail.com
4 Year Total Pharmaceutical Market
Muhammad Ali 8
Therapeutic Class Value in Pkr
Growth
(%)
2015 275,522,458,199 12.67
2014 244,542,382,117 11.47
2013 219,376,114,009 15.47
2012 189,992,366,778 14.83

9. Phr_ali91@hotmail.com
Pakistan Pharmaceutical Growth Trend
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
2012 2013 2014 2015
Growth Trend
Muhammad Ali 9

10. Phr_ali91@hotmail.com
Therapeutic Categories in Pakistan
Muhammad Ali 10
No. Therapeutic Class Value in Pkr
Growth
(%)
Share
(%)
1 SYSTEMIC ANTI-INFECTIVES 65,271,177,742 17.12 23.69
2 ALIMENTARY T.& METABOLISM 61,287,877,927 11.37 22.24
3 NERVOUS SYSTEM 23,587,349,044 15.83 8.56
4 MUSCULO-SKELETAL SYSTEM 20,603,686,637 10.30 7.48
5 CARDIOVASCULAR SYSTEM 20,226,585,410 13.66 7.34
6 RESPIRATORY SYSTEM 18,622,187,466 7.03 6.76
7 VARIOUS 17,780,051,854 12.51 6.45
8 DERMATOLOGICALS 9,404,737,949 12.68 3.41
9 BLOOD + B.FORMING ORGANS 9,195,753,746 9.84 3.34
10 G.U.SYSTEM & SEX HORMONES 8,187,827,556 13.17 2.97
11 PARASITOLOGY 5,861,814,990 3.69 2.13
12 SENSORY ORGANS 5,024,118,048 9.71 1.82
13 ANTINEOPLAST+IMMUNOMODUL 4,722,997,652 8.99 1.71
14 HOSPITAL SOLUTIONS 2,644,284,870 2.47 0.96
15 SYSTEMIC HORMONES 2,338,086,047 13.03 0.85
16 DIAGNOSTIC AGENTS 763,921,261 33.92 0.28

11. Phr_ali91@hotmail.com
Therapeutic Categories In Pakistan And Their Share
Muhammad Ali 11
SYSTEMIC ANTI-
INFECTIVES
24%
ALIMENTARY T.&
METABOLISM
22%
NERVOUS SYSTEM
9%
MUSCULO-
SKELETAL SYSTEM
7%
CARDIOVASCULAR
SYSTEM
7%
RESPIRATORY
SYSTEM
7%
VARIOUS
6%
DERMATOLOGICALS
3%
BLOOD +
B.FORMING
ORGANS
3%
G.U.SYSTEM &
SEX HORMONES
3%
PARASITOLOGY
2%
SENSORY ORGANS
2%
ANTINEOPLAST+IMM
UNOMODUL
2%
HOSPITAL
SOLUTIONS
1%
SYSTEMIC
HORMONES
1%
DIAGNOSTIC
AGENTS
0%

12. Phr_ali91@hotmail.com
Area-wise Sales Performance of the Pakistan Retail
Pharmaceutical Market
Muhammad Ali 12
South
28%
Central
31%
North
37%
Quetta
4%

13. Phr_ali91@hotmail.com
Leading 20 Pharmaceutical Companies in Pakistan
Muhammad Ali 13
No. Name of the Manufacturer Value in Pkr
Growth
%
Contribution
1 GLAXOSMITHKLINE 27,184,502,037 5.19 9.87
2 ABBOTT LAB PAK LTD 17,629,304,945 10.78 6.40
3 GETZ PHARMA 15,867,952,345 20.49 5.76
4 SAMI 13,537,589,986 17.48 4.91
5 NOVARTIS PH.PAK LT 10,387,492,311 3.06 3.77
6 PFIZER INC 9,599,836,292 7.75 3.48
7 SANOFI-AVENTIS PAK 9,469,329,278 6.04 3.44
8 THE SEARLE COMPANY 9,231,864,787 14.40 3.35
9 OBS 8,265,643,835 11.42 3.00
10 FEROZSONS 8,204,743,653 199.13 2.98
11 HILTON 7,525,792,223 10.87 2.73
12 MERCK (PRIVATE) LT 6,968,467,422 8.31 2.53
13 BOSCH 6,604,996,794 19.07 2.40
14 HIGH-Q INTL 5,476,781,312 33.15 1.99
15 BARRETT HODGSON 5,194,788,474 18.24 1.89
16 NESTLE PAKISTAN LT 4,781,274,202 6.53 1.74
17 ATCO 4,691,774,642 28.14 1.70
18 MARTIN DOW LIMITED 4,344,133,639 13.05 1.58
19 BAYER PAK PVT LTD 4,333,895,653 7.95 1.57
20 INDUS 4,034,617,521 24.11 1.46

14. Phr_ali91@hotmail.com
Leading 20 Pharmaceutical Brands in Pakistan
Muhammad Ali 14
No. Brand Name Manufacturer T.P Value in Pkr
Growth
%
CAGR
1 SOVALDI FZS 32,300.00 4,936,904,550 999.00 0.00
2 AUGMENTIN GSK 1,089.79 3,997,469,055 8.21 6.18
3 RISEK GTZ 652.80 2,518,579,324 21.51 23.80
4 BRUFEN AB& 1,537.36 2,221,970,523 9.36 13.76
5 NOVIDAT SAM 1,387.50 2,178,633,617 15.13 17.87
6 PANADOL GSK 255.00 2,047,597,480 16.66 24.83
7 OXIDIL SAM 616.25 1,940,007,374 12.40 20.44
8 VELOSEF GSK 951.61 1,900,787,162 2.06 8.07
9 HUMULIN 70/30 LLY 1,513.85 1,667,409,776 9.61 16.45
10 CAC 1000 PLUS NO- 808.86 1,612,096,203 -1.69 13.34
11 FLAGYL S.A 572.13 1,586,246,136 8.37 6.89
12 AMOXIL GSK 2,361.68 1,564,911,527 3.83 3.71
13 METHYCOBAL HL. 2,040.08 1,477,372,354 13.85 13.37
14 MEIJI FM-T MEI 2,888.00 1,282,581,890 24.55 14.96
15 CEFSPAN BGO 976.23 1,254,467,973 23.46 22.78
16 PONSTAN PFZ 1,139.10 1,224,542,864 0.66 3.20
17 BETNOVATE N GSK 293.95 1,205,253,013 29.11 14.02
18 LACTOGEN 1 NES 616.00 1,179,269,599 6.19 12.34
19 ENSURE AN. 11,974.28 1,174,832,033 13.77 16.95
20 GETRYL GTZ 708.90 1,120,170,506 15.05 18.53

15. Phr_ali91@hotmail.com
Leading 20 Molecules in Pakistan
Muhammad Ali 15
No. Molecules Value in Pkr
Growth
%
CAGR
1 INFANT MILKS 11,669,193,037 12.90 17.36
2 CEFTRIAXONE 7,194,281,094 13.27 14.79
3 CEFIXIME 6,227,447,519 16.56 17.30
4 CIPROFLOXACIN 6,145,148,785 13.02 12.11
5 DICLOFENAC 5,961,298,419 8.63 11.44
6 AMOXICILLIN+CLAVULANIC ACID 5,735,836,098 10.10 9.93
7 OMEPRAZOLE 5,683,151,502 15.62 20.24
8 SOFOSBUVIR 4,936,904,550 999.00 0.00
9 PARACETAMOL 4,010,436,179 11.57 15.22
10 ESOMEPRAZOLE 3,859,594,776 19.86 22.40
11 MECOBALAMIN 3,064,376,178 14.37 12.70
12 CLARITHROMYCIN 2,698,423,662 5.28 13.59
13 INSULIN HUMAN BASE+INSULIN HUMAN ISOPHANE 2,657,783,525 14.34 21.51
14 CEFRADINE 2,519,965,142 3.83 6.60
15 LEVOFLOXACIN 2,503,911,274 7.60 8.32
16 IBUPROFEN 2,461,647,875 8.12 12.03
17 GLIMEPIRIDE 2,320,009,436 13.17 14.34
18 MONTELUKAST 2,186,210,435 8.25 13.73
19 AMOXICILLIN 2,142,858,767 -1.44 0.24
20 METRONIDAZOLE 2,006,377,208 5.91 7.24

16. Phr_ali91@hotmail.com
The Product
• The Product Pharmaceutical products are used in the treatment of
diseases hence called “Drug”
• Every operation pertaining to the drugs including import, manufacturing &
distribution is governed by “The Drugs Act 1976”.
• The Product Drugs are manufactured under the strict quality standards
called GMP (good manufacturing practices)
• No product can be marketed/distributed unless registered by the Ministry
of Health, Pakistan
Muhammad Ali 16

17. Phr_ali91@hotmail.com
The Price
The key factor affecting the price of drugs include but not limited to
• uniqueness (availability) of the product
• the country from where final dosage form or the main raw
materials are imported
• process steps involved in manufacturing
• size of production (economies of scale)
Muhammad Ali 17

18. Phr_ali91@hotmail.com
The Price
• Price structure Cost of raw/packaging materials
• Cost of conversion
• Cost of distribution
• Distributor margin
• Retailer margin
• Cost of promotion
• The cost of drugs is higher than the profits associated with them
Muhammad Ali 18

19. Phr_ali91@hotmail.com
Major Trading Partners of Pakistan in Pharmaceutical
Products
Muhammad Ali 19
Export
partners
Exported
value 2013
(Million US
$)
Percentage
share in
Pakistan’s
pharmaceut
ical exports
Import
partners
Imported
value 2012
(Million
US $)
Percentage
share in
Pakistan’s
pharmaceut
ical imports
Afghanistan 42.52 25.1 Denmark 191.97 28.5
Sri Lanka 17.49 10.3 Switzerland 93.67 13.9
Viet Nam 13.85 8.2 Germany 51.77 7.7
Philippines 11.94 7.0 Belgium 46.62 6.9
Lithuania 8.90 5.3 Italy 36.31 5.4

20. Phr_ali91@hotmail.com
References
• Pakistan Demography Profile from World fact book
• All data related to therapeutic class ,Top Pharmaceutical, Top Brands, Top
Molecules (IMS Q4 2015).
• Healthcare System Structure data obtained from
– PMDC website
– i) Health Division. ii) Provincial Health Directorates.
• Trading Partners data from India-Pakistan Trade: A Case Study of the
Pharmaceutical Sector by Vaqar Ahmed ,Samavia Batool December 2014
Muhammad Ali 20

21. Phr_ali91@hotmail.com
Thank you
Muhammad Ali 21